Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
[PARIS] France's Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.
Blueprint is a specialist in treatments for systemic mastocytosis, a rare blood disorder.
The two companies said on Monday (Jun 2) that Sanofi would initially pay US$129.00 per share in cash, or around US$9.1 billion. Blueprint shares jumped 27 per cent to US$128.74 in premarket trade. Sanofi stock was down about 1 per cent.
Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions.
However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called 'smoker's lung' failed a late-stage trial.
The Blueprint acquisition 'represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company,' said Sanofi CEO Paul Hudson.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the US and the EU, and a promising advanced and early-stage immunology pipeline.
Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells – a type of white blood cell. It triggers a continuous allergic response.
The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology.
The deal makes 'strategic and financial sense', said JPMorgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around US$2 billion by fiscal year 2030.
'We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time,' they added.
It is the latest in a series of deals by Sanofi. Last month, it announced the US$470 million purchase of Vigil Neuroscience and in January 2024 it struck a US$2.2 billion deal for US biotech firm Inhibrx.
Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals.
The company has said it plans to invest at least US$20 billion in the US through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing.
Besides US$129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of US$2 and US$4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, is US$9.5 billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals. REUTERS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
29 minutes ago
- Business Times
Ant unit to seek stablecoin permits in Hong Kong, Singapore: sources
[HONG KONG] Jack Ma-backed Ant Group's international unit is planning to apply for stablecoin licences in Singapore and Hong Kong, according to people familiar with the matter. Singapore-based Ant International will apply for the stablecoin issuer's licence in Hong Kong as soon as the city's Stablecoins Ordinance goes into effect in August, the people said, asking not to be identified because the matter is private. As well as Singapore, the company is also planning to seek a permit in Luxembourg, they added. The move is designed to bolster the fintech firm's blockchain operation underpinning its cross-border payment and treasury management services, the people said. Ant processed more than US$1 trillion of global transactions last year, a third of which were handled by its blockchain-based Whale platform, they said. Ant representatives did not respond to an emailed request for comment. A spokesperson for the Hong Kong Monetary Authority declined to comment. Regulators in Singapore and Luxembourg were not immediately able to comment. Since its record initial public offering was halted in 2020, Ant has been developing new initiatives to drive growth as its lucrative online lending business got handicapped by regulators in China. Overseas, the Ant International arm established an independent board, setting the stage for a spinoff and potential IPO. The unit generated nearly US$3 billion in revenue for 2024 and has produced two consecutive years of adjusted profit, Bloomberg reported in May. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Ant International could fetch an IPO valuation ranging from US$8 billion to US$24 billion if it were to list in Hong Kong, according to Bloomberg Intelligence. Increasingly, the unit's treasury business has shown growth potential due to the sheer amount of transactions it handles for the e-commerce platforms of its affiliate Alibaba Group Holding, as well as external clients. The treasury business, which is underpinned by the Whale platform, uses blockchain technology, including encryption and artificial intelligence, to improve the efficiency and transparency of fund transfers. The Whale platform currently supports multiple tokenized assets from banks and institutions around the world. It uses privacy computing technologies such as homomorphic encryption and enables multiparty verification. The company has signed collaboration agreements with more than 10 banks globally including HSBC Holdings, BNP Paribas, JPMorgan Chase and Standard Chartered. This week, it also formed a strategic partnership with Deutsche Bank to work on payment solutions and treasury management. Stablecoins are digital assets designed to hold a steady value, usually pegged to another currency. They are crucial to the functioning of crypto markets, with about US$243 billion of them in circulation in May. Regulators around the world are trying to put rules around the sector, fearing the risk of stablecoin crashes and the potential for massive money laundering. US lawmakers are working on legislation to regulate stablecoin companies. As crypto adoption has grown, many companies have slowly made their way into the space, including financial and technology heavyweights. A high-profile attempt by Facebook and Instagram owner Meta Platforms to launch a stablecoin in 2019 later unravelled after a backlash. The rollout in 2023 of a stablecoin from PayPal Holdings marked the first effort from a big financial company. There are also tokens that can act like stablecoins for use as collateral during trading, like tokenized money market funds. Asset managers including BlackRock and Franklin Templeton have created these kinds of products in recent years. BLOOMBERG
Business Times
43 minutes ago
- Business Times
Indonesia's Prabowo to meet Putin in Russia for talks
[JAKARTA] Indonesia President Prabowo Subianto will meet counterpart Vladimir Putin this month on his first visit to Russia since taking office, officials said on Thursday (Jun 12), as South-east Asia's biggest economy seeks to boost ties with Moscow. Jakarta maintains a neutral foreign policy, refusing to take sides in the Ukraine conflict or in the competition between Washington and Beijing, but Prabowo has touted stronger relations with Moscow. He will visit Russia from June 18-20 to hold talks with Putin and attend an economic forum in Saint Petersburg, where he will deliver a speech, foreign ministry spokesman Rolliansyah Soemirat told reporters. 'The president and a limited number of delegates are scheduled to visit St Petersburg, Russia, on June 18-20. This visit is to fulfil the invitation from the Russian President, Vladimir Putin, to a bilateral meeting,' Rolliansyah said. 'The bilateral meeting is expected to discuss the development of bilateral cooperation, as well as a discussion between leaders on the regional and global issues that become a common concern,' he said. Prabowo will visit Singapore on Monday to attend a leaders' retreat, where he will meet the country's prime minister and president, before flying to Russia, Rolliansyah said. A NEWSLETTER FOR YOU Friday, 8.30 am Asean Business Business insights centering on South-east Asia's fast-growing economies. Sign Up Sign Up Presidential spokesman Philips Vermonte also confirmed the planned trips to AFP. Prabowo visited Putin in Moscow last year before being inaugurated as Indonesia's new president in October, calling Russia a 'great friend'. The two nations held their first joint naval drills on Java island in November and Prabowo later hosted top Russian security official Sergei Shoigu for talks in the capital Jakarta. Prabowo has pledged to be bolder on the world stage compared with his predecessor Joko Widodo. Jakarta has billion-dollar trade ties with Moscow, yet major arms imports have stalled in recent years after Russia seized Crimea in 2014 and launched its full-scale military offensive on Ukraine in 2022. However, since becoming defence minister in 2019, Prabowo has kept alive a US$1.1 billion Russian fighter jet deal agreed a year earlier, despite the reported threat of US sanctions. AFP
Business Times
43 minutes ago
- Business Times
SGX securities turnover rises 1% in May, volume down 18%
[SINGAPORE] The total securities market turnover value on the Singapore Exchange (SGX) edged up 1 per cent year on year to S$26.9 billion, supported by institutional hedging activity and continued demand for safe-haven and dividend-yielding stocks. The securities daily average value rose 6 per cent on year to about S$1.3 billion. May's total market turnover volume dropped 18 per cent to 22.3 billion shares, from 27.3 billion shares in the same month the year before, said the bourse operator in its monthly market statistics report on Monday (Jun 9). One bright spot was derivatives, where the traded volume increased 6 per cent to 25.4 million contracts in May. Derivatives daily average volume climbed 11 per cent to 1.3 million contracts. The Straits Times Index (STI) in May came close to the all-time high posted in March after it advanced 1.6 per cent month on month to 3,894.61. On Mar 28, it rose above 4,000 for the first time. May's performance was due to 'Singapore's appeal to investors as a flight-to-quality venue', said SGX. Its report also stated that market turnover value of exchange-traded funds (ETF) increased 22 per cent year on year in May to S$376 million, as market participants continued to favour safe-haven and higher dividend-yielding stocks. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The SPDR Gold Shares ETF recorded its 12th consecutive month of gains, bringing net inflows over the one-year period to S$500 million. Meanwhile, net inflows into the two STI ETFs crossed S$60 million in May – the highest since September 2020. The report highlighted the SGX FTSE China A50 Index Futures as a standout performer, with trading volume rising 4 per cent year on year to 7.8 million contracts. SGX said the SGX Equity Derivatives bellwether remains the world's most liquid international futures contract for Chinese equities. The bourse operator listed the won as one of the forex futures outperformers. The daily average value of the SGX KRW/USD FX Futures increased 143 per cent year on year to a monthly record of 38,294 lots, or a notional US$685 million, in May. It said this was in part due to the unprecedented volatility in the Taiwan dollar, which spilled over to emerging Asia currencies – notably the Korean won. The SGX KRW/USD Mini Futures similarly attracted a significant influx of new participants, as did SGX USD/CNH Options, which posted a single-day open interest record of 8,189 lots, or a notional US$818 million. In commodities, traded volume in petrochemicals derivatives more than doubled year on year in May to the equivalent of 4.4 million metric tonnes (MT), with average monthly open interest surpassing three million MT amid a rebound in physical cargo prices. On May 13, SGX Commodities cleared a record single-day volume of 500,000 MT in petrochemicals contracts. SGX said in its monthly report that the Singapore stock market continued to stand out for its 'quality and value to investors', with strong institutional hedging activity as investors recalibrated portfolios in response to ongoing market uncertainty. As at 3.59 pm on Thursday, shares of SGX were up 0.6 per cent or S$0.08 at S$13.86.
